Jobs at regeneron

About regeneron

At Regeneron, we're in it for good. For science that dares. For breakthroughs that change what's possible. For groundbreaking new medicines. Because giving up is never an option. Our mission is to use the power of science to bring new medicines to patients ... over and over again. We are a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, almost all of which were homegrown in our laboratories. Regeneron's medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases and rare diseases. Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite ® , which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® (RGC) and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases. Founded and led by physician-scientists, our leadership team includes Nobel Laureates and eight members of the National Academy of Sciences who guide our science-first approach. Developing life-transforming treatments is no small feat. Decades of investment and perseverance have brought us to where we are today. of colleagues volunteered globally - twice the average participation rate (CECP 2025) waste diverted from landfill by recycling, beneficial reuse or composting Civic 50 list of most community-minded companies in the U.S., 2025 RGC research reveals rare variants in CHRNB3 gene associated with reduced cigarette consumption. Our pursuit of scientific innovation continues to push the boundaries of science and improve our world. Hear our leaders reflect on our progress and vision for the future. We take a highly collaborative approach to science and drug development and prioritize investment in technology and innovation. More than 15,400 of our colleagues work across the globe with offices in 12 countries and clinical trials underway in more than 50 countries. You are now leaving Regeneron.com to visit another Regeneron website.

Company Address

More from regeneron